1.
Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults
by Sun, Luanluan
Nature medicine, 2019-04, Vol.25 (4), p.569-574
2.
Effects of intermittent fasting on body composition and clinical health markers in humans
by Tinsley, Grant M
Nutrition reviews, 2015-10, Vol.73 (10), p.661-674
3.
Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease
by Myasoedova, Elena
Annals of the rheumatic diseases, 2011-03, Vol.70 (3), p.482-487
4.
Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial
by Panahi, Yunes
Complementary therapies in medicine, 2017, Vol.33, p.1-5
5.
Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk
by His, Mathilde
European journal of epidemiology, 2014-01-01, Vol.29 (2), p.119-132
6.
Impact of different training modalities on glycaemic control and blood lipids in patients with type 2 diabetes: a systematic review and network meta-analysis
by Schwingshackl, Lukas
Diabetologia, 2014-07-05, Vol.57 (9), p.1789-1797
7.
Beneficial effects of Bifidobacterium lactis on lipid profile and cytokines in patients with metabolic syndrome: A randomized trial. Effects of probiotics on metabolic syndrome
by Bernini, Luciana Jesus
Nutrition (Burbank, Los Angeles County, Calif.), 2016-06, Vol.32 (6), p.716-719
8.
Long-term air pollution exposure and risk factors for cardiovascular diseases among the elderly in Taiwan
by Chuang, Kai-Jen
Occupational and environmental medicine (London, England), 2011-01, Vol.68 (1), p.64-68
9.
30-Year Trends in Serum Lipids Among United States Adults: Results from the National Health and Nutrition Examination Surveys II, III, and 1999–2006
by Cohen, Jerome D., MD
The American journal of cardiology, 2010, Vol.106 (7), p.969-975
10.
Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk
by Humphries, S E
Journal of medical genetics, 2006-12, Vol.43 (12), p.943-949
11.
Gain-of-Function Lipoprotein Lipase Variant rs13702 Modulates Lipid Traits through Disruption of a MicroRNA-410 Seed Site
by Richardson, Kris
American journal of human genetics, 2013-01-10, Vol.92 (1), p.5-14
12.
Effects of choline on health across the life course: a systematic review
by Leermakers, Lisan
Nutrition reviews, 2015, Vol.73 (8), p.500-522
13.
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
by MATIKAINEN, N
Diabetologia, 2006, Vol.49 (9), p.2049-2057
14.
Postprandial Hyperglycemia/Hyperlipidemia (Postprandial Dysmetabolism) Is a Cardiovascular Risk Factor
by O’Keefe, James H., MD
The American journal of cardiology, 2007, Vol.100 (5), p.899-904
15.
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
by Van Gaal, Luc F
The Lancet (British edition), 2005, Vol.365 (9468), p.1389-1397
16.
Effect of an advanced glycation end product-restricted diet and exercise on metabolic parameters in adult overweight men
by Macías-Cervantes, Maciste Habacuc, M.D., Ph.D
Nutrition (Burbank, Los Angeles County, Calif.), 2015, Vol.31 (3), p.446-451
17.
Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes
by Ahrén, Bo
The journal of clinical endocrinology and metabolism, 2004-05, Vol.89 (5), p.2078-2084
18.
Lipid profile changes after pomegranate consumption: A systematic review and meta-analysis of randomized controlled trials
by Sahebkar, Amirhossein
Phytomedicine (Stuttgart), 2016-10-15, Vol.23 (11), p.1103-1112
19.
Nuts and legume seeds for cardiovascular risk reduction: scientific evidence and mechanisms of action
by Souza, Rávila G. M
Nutrition reviews, 2015-06, Vol.73 (6), p.335-347
20.
Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study
by Eliasson, B
Diabetologia, 2012, Vol.55 (4), p.915-925
